Europe
Expedeon AG announced that the Annual General Meeting held in Heidelberg yesterday, July 09, 2019, approved all management proposals.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce its intention to appoint Dr Jim Esinhart as a Non-Executive Director of the Company.
Companies from across Europe, Asia and around the globe share pipeline and business updates.
Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action.
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
NANOBIOTIX announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR3 in patients with advanced STS have been published online in The Lancet Oncology.
Biofrontera AG, an international biopharmaceutical company, reports preliminary unaudited revenue for the first six months of fiscal year 2019.
Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies
Summit Therapeutics plc announces that it has demonstrated the potential of its DDS-04 series of new class antibiotics as an Enterobacteriaceae-targeted treatment through in vivo proof of concept data in sepsis and pneumonia animal models.
PRESS RELEASES